中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月8日星期二
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (17): 100-103    
  肿瘤医学 本期目录 | 过刊浏览 | 高级检索 |
药物结合物理疗法在胸腔镜肺癌根治术后患者静脉血栓栓塞症预防中的应用效果
江文坛 吴佳云 吴敬阳 林贤宾 林良安 杨建胜▲
福建医科大学附属第二医院胸心血管外科
Effect of drug combined with physical therapy in the prevention of venous thromboembolism after thoracoscopic radical resection of lung cancer
JIANG Wentan WU Jiayun WU Jingyang LIN Xianbin LIN Liang′an YANG Jiansheng▲
Department of Thoracic and Cardiovascular Surgery,the Second Affiliated Hospital of Fujian Medical University
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨药物结合物理疗法在胸腔镜肺癌根治术后患者静脉血栓栓塞症预防中的应用效果。方法 选取2016年1月至2020年12月福建医科大学附属第二医院300 例胸腔镜肺癌根治术后患者作为研究对象,根据随机数字表法分成联合组(n=150)和物理组(n=150)。物理组采用物理预防,联合组在物理组的基础上使用药物预防。比较两组患者治疗前后血液相关指标[血红蛋白(Hb)、D-二聚体、纤维蛋白原(FIB)]变化及静脉血栓栓塞症、出血发生率。结果 两组患者的胸管引流量、胸管滞留时间比较,差异无统计学意义(P>0.05)。联合组的术后住院时间短于物理组,差异有统计学意义(P<0.05)。两组患者治疗后的Hb 水平比较,差异无统计学意义(P>0.05)。联合组治疗后的D-二聚体、FIB 水平低于物理组,差异有统计学意义(P<0.05)。联合组的静脉血栓栓塞症总发生率低于物理组,差异有统计学意义(P<0.05)。两组患者的出血发生率比较,差异无统计学意义(P>0.05)。结论 采取药物预防结合物理预防可以降低胸腔镜肺癌根治术后患者的静脉血栓栓塞症发生率,并缩短术后住院时间,且不增加术后引流量,不延长胸管滞留时间,安全性好,可作为肺癌术后预防静脉血栓栓塞症的重要措施。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
江文坛
吴佳云
吴敬阳
林贤宾
林良安
杨建胜
关键词 胸腔镜肺癌根治术静脉血栓栓塞症静脉血栓栓塞症发生率预防措施    
Abstract:Objective To explore the effect of drug combined with physical therapy in the prevention of venous thromboembolism after thoracoscopic radical resection of lung cancer.Methods A total of 300 patients after thoracoscopic radical resection of lung cancer in the Second Affiliated Hospital of Fujian Medical University from January 2016 to December 2020 were selected as the research objects.According to the random number table method,they were divided into combined group (n=150) and physical group (n=150).The physical group used physical prevention,and the combined group used drug prevention on the basis of the physical group.The changes of blood related indexes(hemoglobin [Hb],D-dimer,fibrinogen [FIB]) before and after treatment and the incidence of venous thromboembolism and bleeding were compared between the two groups.Results There were no significant differences between the two groups in chest tube drainage volume and chest tube retention time (P>0.05).The postoperative hospital stay in the combined group was shorter than that in the physical group,and the difference was statistically significant (P<0.05).There was no significant difference in Hb level between the two groups after treatment (P>0.05).The levels of D-dimer and FIB in the combined group were lower than the physical group,the differences were statistically significant (P<0.05).The total incidence of venous thromboembolism was lower than the physical group,and the difference was statistically significant (P<0.05).There was no significant difference in the incidence of bleeding between the two groups (P>0.05).Conclusion Drug combined with physical therapy can reduce the incidence of venous thromboembolism in patients with radical thoracoscopic pulmonary cancer and shorten the postoperative hospitalization time,do not increase postoperative flow and prolong the retention of thoracic tube,which can serve as an important measure to prevent pulmonary cancer.
Key wordsRadical thoracoscopic lung cancer    Venous thromboembolism    Incidence of venous thromboembolism    Preventive measures
    
基金资助:福建省自然科学基金资助项目(2020J01207)。
通讯作者: 杨建胜(1967-),男,福建石狮人,博士,主任医师,研究方向:肺癌、食管癌、纵隔肿瘤的微创治疗;血管疾病外科治疗。   
作者简介: 江文坛(1982-),男,福建漳州人,硕士,研究方向:肺癌、食管癌、纵隔肿瘤的微创治疗及围手术期管理;肺癌患者的循环肿瘤细胞检测及基因检测。
引用本文:   
江文坛;吴佳云;吴敬阳;林贤宾;林良安;杨建胜. 药物结合物理疗法在胸腔镜肺癌根治术后患者静脉血栓栓塞症预防中的应用效果[J]. 中国当代医药, 2022, 29(17): 100-103.
JIANG Wentan; WU Jiayun ;WU Jingyang ;LIN Xianbin; LIN Liang′an ;YANG Jiansheng▲. Effect of drug combined with physical therapy in the prevention of venous thromboembolism after thoracoscopic radical resection of lung cancer. 中国当代医药, 2022, 29(17): 100-103.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I17/100
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载